Docket #: S06-058

Engineered EGF polypeptides for improved epidermal and epithelial wound healing

Applications

- Treatment of chronic wounds
- Cosmetic Application

Advantages

- EGF mutants have about 30 times more receptor-binding affinity than natural EGF

Publications

- US patent 8,247,531: Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
- Cochran JR, Kim YS, Lippow SM, Rao B, Wittrup KD. Improved mutants from directed evolution are biased to orthologous substitutions. Protein Engineering, Design & Selection. 2006 Jun;19(6):245-53.

Patents

- Published Application: WO2007109673
- Published Application: 20080249008
- Issued: 8,247,531 (USA)

Innovators

- Jennifer Cochran
- Karl Wittrup

Licensing Contact

Kimberly Griffin

Technology Licensing and Strategic Alliances Manager

Email